The University of Chicago Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Nishant Agrawal and Evgeny Izumchenko.
Nishant Agrawal
Connection Strength
4.227
Evgeny Izumchenko
  1. Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer. Clin Cancer Res. 2025 Aug 01; 31(15):3150-3159.
    View in: PubMed
    Score: 0.236
  2. Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA. Oral Oncol. 2025 Aug; 167:107445.
    View in: PubMed
    Score: 0.234
  3. PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands. J Exp Clin Cancer Res. 2025 Jan 11; 44(1):11.
    View in: PubMed
    Score: 0.227
  4. Circulating tumor DNA in head and neck squamous cell carcinoma-current status and future prospects. Acad Oncol. 2024; 1(2).
    View in: PubMed
    Score: 0.226
  5. Microbial Changes Associated With Oral Cavity Cancer Progression. Otolaryngol Head Neck Surg. 2023 06; 168(6):1443-1452.
    View in: PubMed
    Score: 0.198
  6. Author Correction: A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer. Nat Commun. 2022 Dec 21; 13(1):7865.
    View in: PubMed
    Score: 0.197
  7. A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer. Nat Commun. 2022 08 17; 13(1):4829.
    View in: PubMed
    Score: 0.192
  8. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death Dis. 2022 08 05; 13(8):678.
    View in: PubMed
    Score: 0.192
  9. Molecular drivers of oral cavity squamous cell carcinoma in non-smoking and non-drinking patients: what do we know so far? Oncol Rev. 2022 Feb 22; 16(1):549.
    View in: PubMed
    Score: 0.186
  10. Application of liquid biopsy as multi-functional biomarkers in head and neck cancer. Br J Cancer. 2022 02; 126(3):361-370.
    View in: PubMed
    Score: 0.183
  11. A robust and interpretable gene signature for predicting the lymph node status of primary T1/T2 oral cavity squamous cell carcinoma. Int J Cancer. 2022 02 01; 150(3):450-460.
    View in: PubMed
    Score: 0.181
  12. Doublecortin-Like Kinase 1 (DCLK1) Is a Novel NOTCH Pathway Signaling Regulator in Head and Neck Squamous Cell Carcinoma. Front Oncol. 2021; 11:677051.
    View in: PubMed
    Score: 0.178
  13. Sensitive detection and quantification of SARS-CoV-2 in saliva. Sci Rep. 2021 06 14; 11(1):12425.
    View in: PubMed
    Score: 0.177
  14. Ultrasensitive detection of tumor-specific mutations in saliva of patients with oral cavity squamous cell carcinoma. Cancer. 2021 05 15; 127(10):1576-1589.
    View in: PubMed
    Score: 0.171
  15. Sensitive detection and quantification of SARS-CoV-2 in saliva. medRxiv. 2020 Dec 07.
    View in: PubMed
    Score: 0.171
  16. Molecular biology of oral cavity squamous cell carcinoma. Oral Oncol. 2020 03; 102:104552.
    View in: PubMed
    Score: 0.160
  17. Somatic mitochondrial mutation discovery using ultra-deep sequencing of the mitochondrial genome reveals spatial tumor heterogeneity in head and neck squamous cell carcinoma. Cancer Lett. 2020 02 28; 471:49-60.
    View in: PubMed
    Score: 0.159
  18. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat Commun. 2015 Sep 16; 6:8258.
    View in: PubMed
    Score: 0.119
  19. Notch1 mutations are drivers of oral tumorigenesis. Cancer Prev Res (Phila). 2015 Apr; 8(4):277-286.
    View in: PubMed
    Score: 0.112
  20. Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207]. Oral Oncol. 2025 Oct; 169:107510.
    View in: PubMed
    Score: 0.059
  21. Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 May 01; 11(5):492-501.
    View in: PubMed
    Score: 0.058
  22. Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas. Oral Oncol. 2025 Apr; 163:107207.
    View in: PubMed
    Score: 0.057
  23. Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
    View in: PubMed
    Score: 0.055
  24. Acquired resistance to immunotherapy and chemoradiation in MYC amplified head and neck cancer. NPJ Precis Oncol. 2024 May 23; 8(1):114.
    View in: PubMed
    Score: 0.054
  25. Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma. Oral Oncol. 2024 Feb; 149:106688.
    View in: PubMed
    Score: 0.053
  26. A comprehensive AI-driven analysis of large-scale omic datasets reveals novel dual-purpose targets for the treatment of cancer and aging. Aging Cell. 2023 12; 22(12):e14017.
    View in: PubMed
    Score: 0.052
  27. Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
    View in: PubMed
    Score: 0.048
  28. Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma. JAMA Netw Open. 2022 04 01; 5(4):e227240.
    View in: PubMed
    Score: 0.047
  29. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
    View in: PubMed
    Score: 0.046
  30. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021 11; 122:105566.
    View in: PubMed
    Score: 0.045
  31. COVIDomic: A multi-modal cloud-based platform for identification of risk factors associated with COVID-19 severity. PLoS Comput Biol. 2021 07; 17(7):e1009183.
    View in: PubMed
    Score: 0.045
  32. TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients. J Exp Clin Cancer Res. 2020 Sep 23; 39(1):200.
    View in: PubMed
    Score: 0.042
  33. Immune profiles in primary squamous cell carcinoma of the head and neck. Oral Oncol. 2019 09; 96:77-88.
    View in: PubMed
    Score: 0.039
  34. Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features. Cancer Prev Res (Phila). 2015 Apr; 8(4):287-95.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.